Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of H009 injection dosing regimens versus esomeprazole after endoscopic hemostasis for peptic ulcer upper gastrointestinal bleeding
ChiCTR2200058143Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of H009 and esomeprazole in Peptic ulcer disease (PUD) and upper gastrointestinal bleeding (UGIB) (3 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Rate of no rebleeding within 72 hours after initiation of administration (endoscopic evaluation). Planned start Apr 2022; status: not yet recruiting.
02
Drugs
H009esomeprazole
03
Conditions
Peptic ulcer disease (PUD)upper gastrointestinal bleeding (UGIB)
Beyond the preview
Go deeper on ChiCTR2200058143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058143.